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Chronic fatigue syndrome (CFS) refers to a constellation of
symptoms, characterised by persistent and disabling fatigue
that is typically made worse by exertion. Some believe that
myalgic encephalomyelitis (ME) is another name for the
same condition; others regard it as different. Whatever it is
called, CFS or ME is an ‘orphan’ condition owned and cared
for by no particular discipline. ME is classiﬁed within the
International Classiﬁcation of Diseases (ICD-10) as a
neurological condition (G93.3),1 yet the majority of UK
neurologists do not regard it as such.2 CFS may also be
classiﬁed as neurasthenia (F48), a diagnosis found in the
ICD-10 chapter on mental and behavioural disorders, or as a
non-speciﬁc somatoform disorder.1 However, psychiatrists
rarely see the illness as a condition that they should treat
and many do not regard it as a mental illness. Therefore,
while there is a consensus that CFS exists as a discrete
syndrome, there is little agreement about how it should be
classiﬁed, who should treat patients suffering from it, or
how it should be treated.
The PACE trial
The PACE (Pacing, graded Activity and Cognitive behaviour
therapy: a randomised Evaluation) trial aimed to determine
which of the non-drug treatments advocated for CFS
worked best and was safe. The ﬁrst research grant
application to do a trial was submitted in 1998. At that
time, two trials of cognitive-behavioural therapy (CBT) and
two trials of graded exercise therapy (GET) had been
published; these suggested that both were promising
treatments, but neither treatment had been accepted by
patient organisations. Therapeutic nihilism abounded and
rest was often advocated as the only useful treatment.3
This original grant application was unsuccessful and it
took a further 5 years before we obtained funding for a trial.
In those 5 years, the trial design went through two more
iterations. The ﬁrst added a specialist medical care (SMC)
arm to allow comparison of the two new therapies with the
encouragement, education and support of a knowledgeable
doctor. The second iteration was developed in collaboration
with the patient organisation Action for ME, and added a
therapy called pacing, which surveys of their members had
suggested was the most helpful approach. The involvement
of this patient charity, which included the involvement of
the charity’s CEO as an active member of the trial
management committee, was sought to ensure that the
trial addressed the right questions in the right way, and to
maximise the conﬁdence of the patient community in its
ﬁndings.
The concept of pacing had evolved from a strategy used
in chronic pain. It is essentially an approach to management
of the illness in which the patient is helped to better adapt
to the symptoms by living within the limits they impose.
The patient is encouraged to ‘listen to their body’ and to
adopt the right balance between doing too much or too
little. Pacing for CFS had never previously been tested in a
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trial, and the precepts behind it allowed a comparison of
two different models of the illness: one adaptive (pacing),
the other rehabilitative (CBT and GET). A standardised
pacing therapy was produced in collaboration with Action
for ME and Professor Diane Cox of Cumbria University, who
agreed to be the therapy lead, having had extensive
experience in delivering an occupational therapy approach
to CFS that incorporated pacing. We called it ‘adaptive
pacing therapy’ (APT) so as to convey the main aim of the
therapy - to enable the patient to optimally adapt to the
illness.
The PACE trial was ﬁnally funded in 2003.4
Design issues
The PACE trial was designed to compare the efﬁcacy and
safety of SMC alone against SMC with additional APT, CBT
or GET for patients with CFS recruited from six clinics in
England and Scotland. We also sought to determine cost-
effectiveness, mediators and moderators of outcome, as well
as the patients’ long-term outcome. The trial raised a
number of design issues.
Delivery of the therapies
A key design issue was how best to deliver the three
therapies; should the same individuals deliver all three or
should each be given by different people? We decided to
have the most appropriate discipline deliver each therapy:
CBT-trained therapists (clinical psychologists or nurse
therapists) delivered CBT, physiotherapists (there was one
exercise physiologist) delivered GET and occupational
therapists delivered APT. This decision ensured optimal
delivery of each therapy by the therapists most likely to
deliver these therapies in clinical practice, but increased the
risk that the relative effectiveness of the therapies could be
compounded by differences in the effectiveness of the
therapists themselves. Consequently, quality assurance of
therapy delivery was vital. We did this in a number of ways:
manuals for both therapists and patients were written and
iteratively piloted, and extensive training and regular
supervision of the therapists was provided.
Therapy quality was ensured by only allowing therapists
to treat trial patients once their competency had been
established with non-trial patients. Each therapy had a lead
who delivered supervision: these were Mary Burgess, an
authority on CBT for CFS; Jessica Bavinton and Lucy Clark
for GET, a clinical specialist physiotherapist and a research
sports physiologist, respectively; and Diane Cox for APT. All
therapy sessions were audio-recorded to aid supervision and
to allow ratings of therapy quality and ﬁdelity.5 The
treatment manuals we used in the trial are available for
free download at www.pacetrial.org/trialinfo.
Eligibility criteria and outcomes
We decided that only patients who met the Oxford
deﬁnition of CFS would be eligible to participate in the
trial.6 This deﬁnition was widely used, broad and, unlike
others, required fatigue to be the patients’ main complaint.
This helped to differentiate CFS from other syndromes,
such as ﬁbromyalgia, in which fatigue is a common
symptom. We were also interested in knowing whether the
trial ﬁndings applied to the subgroups of patients who met
alternative deﬁnitions of CFS and ME, so we stratiﬁed
treatment allocation by the international criteria for CFS
and also by the London criteria for ME.7,8
The primary outcome was hard to decide on: should it
be fatigue or disability? After much debate, we chose both as
co-primary outcomes because we considered them equally
important aspects of the illness and potentially different in
their response to the different treatments.
In order to measure treatment safety, we chose to
follow the stringent European Union Clinical Trials
Directive for pharmaceutical interventions, a standard
rarely applied to trials of therapies.9 The measures of
safety included adverse events, serious adverse events and
reactions, withdrawal from treatments, a global self-
measure of worsening, and an a priori threshold for
deterioration in physical disability.
We also measured a number of secondary outcomes as
well as potential mediators and moderators. Outcomes were
assessed at baseline, mid-therapy, the end of the main
treatment phase and 1-year follow-up, as well as long-term
follow-up 2.5 years after randomisation.
The analysis
Having two primary outcomes complicated the analysis,
although the size of the trial gave sufﬁcient power. Having
three follow-up assessments allowed us to use a linear
regression model that minimised any effects of the small
amount of missing data, and also allowed us to adjust the
model by factors such as baseline measures. We originally
planned to use a composite outcome measure of the
proportions of participants who met either a 50% reduction
in the outcome score or a set threshold score for
improvement. However, as we prepared our detailed
statistical analysis plan, we quickly realised that a composite
measure would be hard to interpret, and would not allow us
to answer properly our primary questions of efﬁcacy (i.e.
comparing treatment effectiveness at reducing fatigue and
disability). Before any examination of outcome data was
started, and after approval by our independent steering and
data monitoring committees, we decided to modify our
method of analysis to one that simply compared scores
between treatments at follow-up, adjusting the analysis by
baseline scores. We also addressed the potential clustering
effects resulting from different numbers of patients being
treated by the different therapists.
The main results
Overall, we recruited 640 patients.10 Almost all participants
(98%) provided some outcome data, and 95% provided
outcome data at 12 months, with no signiﬁcant differences
between arms in missing data. These very high rates of
follow-up were achieved as a result of the commitment of
the participants and the assiduous work by the research
staff. The strategies used by the latter included offering
convenient interview times (including early evenings),
mailing most questionnaires to allow sufﬁcient time to
answer them before interviews, paying travel expenses,
following up non-attenders expeditiously by mail and
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telephone, offering to see the participants at their homes
and, as a last resort, recording the primary outcomes over
the telephone. However, if we were doing the trial again, we
would seek ethical permission to also offer follow-up by
email, Skype and FaceTime.
Only 8% of participants dropped out of treatment,
again with no signiﬁcant difference in dropouts between
treatment arms. Between 82 and 88% of participants who
received a therapy alongside SMC said that they were
satisﬁed with it, whereas only 50% reported being satisﬁed
with SMC alone.
Analysis of the primary outcomes revealed that both
CBT and GET led to signiﬁcantly greater improvements in
both fatigue and physical disability than did either SMC or
APT. The adjusted effect sizes ranged from 0.5 to 0.8. To our
surprise, there were no signiﬁcant differences between APT
and SMC in either primary outcome.
The differences between treatments for the secondary
outcomes were broadly similar to the primary outcome
comparisons. There were no signiﬁcant differences in any
safety measures between treatment arms. There was also a
similar pattern of results in the two subgroups that met the
alternative criteria for CFS and ME.
The cost of one quality-adjusted life-year (QUALY)
gained was found to be £18 374 for CBT and £23 615 for
GET.11 Both CBT and GET were three times more likely to
lead to recovery from the present episode of illness than
SMC alone.12
We concluded that both CBT and GET were moderately
effective, cost-effective and safe treatments for CFS. These
results were important in conﬁrming to patients, healthcare
professionals and commissioners that the promise of CBT
and GET found in the earlier and small trials was justiﬁed,
and that these treatments were safe to receive, if delivered
as designed by the appropriate therapists.
Implementation
The results of the trial supported the current National
Institute for Health and Care Excellence (NICE) guidelines’
recommendation that ‘cognitive behavioural therapy and/or
graded exercise therapy should be offered to people with
mild or moderate CFS/ME [ . . . ] because currently these
are the interventions for which there is the clearest research
evidence of beneﬁt.’13 The trial results also suggested that
management by pacing, which was notably less effective
than the other therapies, should not be recommended.
Now the trial has been completed and the main
ﬁndings published, there is the challenging business of
implementation within the National Health Service (NHS)
at a time of reducing budgets. Despite the NICE guidelines
suggesting that patients with long-standing CFS should be
seen by specialists,13 many are now being sent to either
Improving Access to Psychological Therapies (IAPT)
services or mental health teams; these services are often
neither conﬁdent nor competent in delivering CFS-speciﬁc
CBT and GET. The evidence suggests that outcomes are
better with specialist CFS services.14,15 Alternative ways of
delivering therapies, such as through the internet and by
telephone, which are easier to access and potentially more
cost-effective, may provide ways to help patients in the
future.16,17
Challenges and solutions
Delivering treatment in a trial like this required the time
and resources to recruit, employ, train and supervise
numerous staff working across a wide geographical area.
We also had to address staff turnover and the consequent
extra training and supervision needed for new staff.
Occasionally, it was necessary to train an existing therapist
in a second therapy, which proved popular with those who
did it. The morale of therapists giving a speciﬁc therapy was
maintained by encouraging them to take ownership of their
manualised therapy, by close supervision, and by peer
support between centres.5
PACE was affected by several external inﬂuences. First,
some patient organisations expressed opposition to the trial
from the time that funding was announced.18 Our under-
standing is that this opposition reﬂected the fact that the
trial did not focus on a biomedical approach to CFS.
Meetings with those who objected did not alter their
concerns and divergent views about the illness and its
management continue to this day.19 Strategies against the
trial have included a public petition to the prime minister
and formal complaints to our funders and publishers.20
None of these complaints have been upheld, but they did
take considerable time to address. A large number of
Freedom of Information Act requests seeking information
on all aspects of the trial have been received since the main
results were published in 2011. Both declined requests that
were appealed all the way up to the Information Tribunal
were rejected, one being considered ‘vexatious’.21 There was
even a debate on the trial in the House of Lords in 2013.22
Our deliberate policy, to help allay concerns about the trial,
was to be as transparent as possible regarding what we did,
while protecting medical conﬁdentiality and our staff; this
included publishing the protocol and the statistical analysis
plan,4,23 and paying for open access to all publications. On a
more positive note, some patient organisations, such as the
Association for Young people with ME (AYME), have
accepted the ﬁndings, and are advising their members
accordingly.24
Second was the challenge of delivering a complex trial
in the NHS. One particular threat was the ‘Agenda for
Change’ which had implications for the salary grades of
therapists. As a result, some of the trial centres interpreted
the fact that the trial therapists had to use a manual to
mean that they were unskilled, and therefore should have
their pay reduced. We were successful in making the case
that the trial therapists were more rather than less skilled
by taking on a research role. We also supported therapists in
their career progression, providing guaranteed employment
beyond the trial, when possible.
The third challenge was longevity. The trial was funded
in 2003; the ﬁrst patient recruited in March 2005; the last
patient followed up by January 2010; the main paper
published in February 2011. Eight years is a long time to
keep a team together and motivated. The co-principal
investigators (PIs) and treatment leaders had an important
role in setting the standards for trial conduct and ensuring
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therapy and research team cohesion and direction. In turn,
the external monitoring and support of the Medical
Research Council, trial steering committee and data
monitoring committees were essential in maintaining the
morale of the PIs. All staff met annually for a team meeting,
which incorporated fun as well as training and education,
supplemented by regular newsletters updating staff about
progress (www.pacetrial.org/trialinfo). It may be that the
external criticisms of the trial enhanced the internal
cohesion and determination shown by the 100 or so staff
involved.
Conclusion
Delivering the PACE trial was an all-consuming, challenging,
but ultimately rewarding task that lasted many years. We
hope that it has provided useful information for patients,
clinicians and commissioners about the efﬁcacy, adverse
effects and cost-effectiveness of rehabilitative interventions
for CFS. We hope that we have also been able to show that it
is possible to deliver a large trial of complex interventions in a
challenging and sometimes hostile environment and to obtain
clear results from it.
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